MIN 102

Drug Profile

MIN 102

Alternative Names: MIN-102

Latest Information Update: 04 Jan 2017

Price : $50

At a glance

  • Originator IDIBELL
  • Developer Minoryx Therapeutics
  • Class Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adrenoleucodystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Adrenoleucodystrophy

Most Recent Events

  • 14 Dec 2016 MIN 102 receives Orphan Drug status for Adrenoleucodystrophy in European Union
  • 14 Dec 2016 Minoryx Therapeutics plans a phase II/III trial for Adrenoleucodystrophy (In adults) in
  • 06 Jul 2016 Phase-I clinical trials in Adrenoleucodystrophy (In volunteers) in unknown country (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top